New hope for controlling Tough-to-Treat breast cancer
NCT ID NCT07207070
Summary
This study is testing if adding a new drug called JS105 to two standard breast cancer medications works better than the standard two-drug combination alone. It is for adults with a specific type of advanced breast cancer that has returned or spread and has a PIK3CA gene mutation. The main goal is to see if the three-drug combo can better control the cancer and delay its progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese Acadamy of Medical Sciences and Peking Union Medical College
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Henan Provincial Cancer Hospital
RECRUITINGZhengzhou, Henan, 450003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.